期刊文献+

注射用重组人尿激酶原治疗急性ST段抬高型心肌梗死的疗效和安全性及影响因素分析 被引量:66

Efficacy and Safety of Injection of Recombinant Human Prourokinase in the Treatment of Acute ST- segment Elevation Myocardial Infarction and Influencing Factors
下载PDF
导出
摘要 目的分析注射用重组人尿激酶原(rh Pro-UK)治疗急性ST段抬高型心肌梗死(STEMI)的疗效、安全性及出血的影响因素。方法选取2013年5月—2015年3月天津市人民医院心脏重症监护室(CCU)病房收治的经rh Pro-UK静脉溶栓治疗且符合纳入与排除标准的STEMI患者87例为研究对象。根据全球急性冠脉综合征(ACS)注册研究(GRACE)评分,将患者分为低危组(GRACE评分〈109分,45例)、中危组(GRACE评分109~140分,29例)、高危组(GRACE评分〉140分,13例);根据心肌梗死溶栓试验(TIMI)危险评分,将患者分为低危组(TIMI危险评分0~3分,49例)、中危组(TIMI危险评分4~6分,24例)和高危组(TIMI危险评分≥7分,14例)。观察并比较不同发病至静脉溶栓治疗时间患者静脉溶栓治疗后30、60、90、120 min的冠状动脉再通率,比较各组出血发生率及主要不良心血管事件(MACE)发生率。出血的影响因素采用多因素Logistic回归分析。绘制GRACE评分、TIMI危险评分预测出血及MACE的受试者工作特征曲线(ROC曲线),计算ROC曲线下面积(AUC)。GRACE评分、TIMI危险评分预测出血及MACE的拟合优度比较采用H-L检验。结果静脉溶栓治疗后30、60、90、120 min总冠状动脉再通率分别为21.8%(19/87)、51.7%(45/87)、65.5%(57/87)、77.0%(67/87)。随着发病至静脉溶栓治疗时间的延长,静脉溶栓治疗后不同时间冠状动脉再通率比较,差异均无统计学意义(P〉0.05)。轻度出血10例(11.5%);MACE发生情况:梗死后心绞痛12例(13.8%)、心律失常8例(9.2%)、再发心肌梗死7例(8.0%)、心力衰竭5例(5.7%)、死亡3例(3.4%)。GRACE评分中危组、高危组出血、MACE发生率均高于GRACE评分低危组,GRACE评分高危组出血、MACE发生率均高于GRACE评分中危组(P〈0.05)。TIMI危险评分中危组、高危组出血、MACE发生率均高于TIMI危险评分低危组 Objective To observe the clinical efficacy and safety of rh Pro-UK in the treatment of ST- segment elevation myocardial infarction( STEMI) and analyze the risk factors for in- hospital bleeding. Methods A total of 87 patients with STEMI after thrombolytic therapy with rh Pro-UK in CCU of Tianjin People' s Hospital from May 2013 to March 2015 who accorded with the inclusion and exclusion criteria were enrolled. According to the score of the Global Registry of Acute Coronary Events( GRACE),we divided the patients into GRACE low- risk group( GRACE 〉109,45 cases),GRACE mid- risk group( GRACE 109 ~ 140,29 cases) and GRACE high- risk group( GRACE 〉140,13 cases). According to Thrombolysis in Myocardial Infarction( TIMI) risk score,we divided the patients into TIMI low- risk group( TIMI 0 ~ 3,49 cases),TIMI mid- risk group( TIMI 4 ~ 6,24 cases) and TIMI high- risk group( TIMI ≥ 7,14 cases). 30,60,90,120 min after thrombolytic therapy,the coronary recanalization rates were observed and compared among patients with different time from onset to thrombolytic therapy. The incidence of bleeding and major adverse cardiac events( MACE) were compared among each group.Influencing factors for bleeding were investigated by multivariate Logistic regression analysis. ROC curves of GRACE score and TIMI risk score predicting bleeding and MACE was made,and AUC values were calculated. H- L test was conducted to compare the goodness of fit between GRACE score and TIMI risk score in the prediction of bleeding and MACE. Results The total coronary recanalization rates were 21. 8%( 19 /87),51. 7%( 45 /87),65. 5%( 57 /87) and 77. 0%( 67 /87) 30 min,60 min,90 min and 120 min after thrombolytic therapy. With the time extending from onset to thrombolytic therapy,there were no significant differences among the coronary recanalization rates of different time after thrombolytic therapy( P〈0. 05). The incidence of minor bleeding was 11. 5%( 10 cases). There were 12 cases of post
出处 《中国全科医学》 CAS CSCD 北大核心 2016年第9期1061-1066,共6页 Chinese General Practice
关键词 心肌梗死 注射用重组人尿激酶原 疗效比较研究 溶栓 GRACE 心肌梗死溶栓试验危险评分 Myocardial infarction Recombinanthuman prourokinase for injection Comparative effectiveness research Thrombolysis GRACE TIMI risk score
  • 相关文献

参考文献20

  • 1China Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Guideline for diagnosis and treatment of patients with ST- elevation myocardial infarction [ J ]. Zhonghua Xin Xue Guan Bing Za Zhi, 2015, 43 (5) : 380 -393. 被引量:1
  • 2Welsh RC, Van de Weft F, Westerhout CM, et al. Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study) [J]. Am J Cardiol, 2014, 114 (6): 811 -819. 被引量:1
  • 3Figueras J, Roca I, Barrab6s JA, et al. Long - term implications of further ST elevation during thrombolytic therapy on left ventrlcular function [J]. Coron Artery Dis, 2013, 24 (6): 455-460. 被引量:1
  • 4张正光.重组人尿激酶原的临床研究概况[J].生物技术通讯,2012,23(2):294-299. 被引量:6
  • 5SunY, Liu X, Guo L, et al. HTUPA as a new thrombolytic agent for acute myocardial infarction: a multicenter, randomized study [ J]. Int J Cardiol, 2014, 172 (2) : 326 -331. 被引量:1
  • 6宋志平,杜丹阳,黄平,黄煜,黄海.急性心肌梗死患者采用重组人尿激酶原溶栓治疗的疗效及安全性分析[J].临床医学工程,2014,21(4):469-470. 被引量:14
  • 7王丽英,王国军,张彦玲,田贵敏,陈亚利.注射用重组人尿激酶原溶栓治疗急性心肌梗死的临床效果观察[J].临床误诊误治,2015,28(5):107-109. 被引量:26
  • 8Bekler A, Altun B, Gazi E, et al. Comparison of the GRACE risk score and the TIMI risk index in predicting the extent and severity ofcoronary artery disease in patients with acute coronary syndrome [ J ]. Anadol J Cardiol, 2015, 15 (10) : 801 -806. 被引量:1
  • 9Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST - elevation myocardial infarction : a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early I trial substudy [ J ]. Circulation. 2000. 102 (17): 2031-2037. 被引量:1
  • 10Tamis -Holland JE, O'Gara P. Highlights from the 2013 ACCF /AHA guidelines for the management of ST - elevation myocardial infarction and beyond [ J]. Clin Cardiol, 2014, 37 (4): 252 - 259. 被引量:1

二级参考文献41

  • 1刘闯,张金盈,黄振文,李华,邱春光,党瑜华,赵洛莎,张彦周,张晓,张慧琴,刘保山.国产注射用重组人尿激酶原治疗急性心肌梗死疗效观察[J].郑州大学学报(医学版),2004,39(6):1051-1054. 被引量:7
  • 2许骥,华琦,刘力松,万云高,李东宝,胥照平,姜燕,杨旭,李天德,胡大一,刘荣坤,杨峥.重组人尿激酶原与尿激酶对急性心肌梗死患者纤溶系统影响的比较[J].首都医科大学学报,2005,26(2):132-135. 被引量:35
  • 3郭瑄,李成祥,贾国良,王海昌,姜燕,冯旭阳,曹丰,郭文怡,王小燕,李伟,党米婵.国产重组人尿激酶原治疗ST段抬高性急性心肌梗死41例[J].第四军医大学学报,2005,26(8):718-720. 被引量:6
  • 4Weaver W D,Hartmann J R,Anderson J L,et al.New recombinant glycosylated prourokinase for treatment of patient with acute myocardial infarction[J].JACC, 1994,24(5):1242-1248. 被引量:1
  • 5Sasahara A A,Barker W M,Weaver W D,et al.Clinical study with the new glycosylated recombinant prourokinase[J].J Vasc Interv Radiol,1995,6(Pt 2 Su):84S-93S. 被引量:1
  • 6Primi trial study group.Randomized double-bllnd trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction[J].Lancet,1989,1:863-867. 被引量:1
  • 7Michels R,Hoffmann H,Windeler J,et al.A double-blind muhicenter comprison of the treatmen of acute myocardial infarction:report of the SUTAMI study group[J].J Thrombosis Thrombolysis,1995,2:117-124. 被引量:1
  • 8B(a)r F W,Meyer J,Vermeer F,et al.Comparison of Saruplase and Alteplase in Acute Myocardial Infarction[J].AM J Cardiol,1997,79:727-732. 被引量:1
  • 9Tebbe U,WindelerJ,Boesl I,et al.the LIMITS Study Group.Thrombolysis with Recombinant Unglycosylated Single-Chain Urokinase-type Plasminogen Activator (Saruplase) in Acute Myocardial Infaction:Influence of Heparin on Early Patency Rate (LIMITS Study),1995,26(2):365-373. 被引量:1
  • 10B(a)r F W,Meyer J,Roland J,et al.Bolus Administration of Europe (BASE),a Pilot Study in Patient with Acute Myocardial Infarction[J].Journal of Thromosis and Thrombolysis,1998,6:147-153. 被引量:1

共引文献40

同被引文献687

引证文献66

二级引证文献363

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部